SOURCE: AspenBio Pharma, Inc.

August 05, 2008 12:45 ET

AspenBio Pharma to Present at the 28th Annual Canaccord Adams Global Growth Conference

CASTLE ROCK, CO--(Marketwire - August 5, 2008) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has been invited to present at the 28th Annual Canaccord Adams Global Growth Conference to be held at the InterContinental Boston on August 12-14, 2008.

AspenBio president and CEO, Richard G. Donnelly, is scheduled to present on Thursday, August 14 at 9:30 a.m. Eastern Time. The presentation will be available via webcast at

Mr. Donnelly will discuss the continued advancement of AppyScore™, the world's first blood-based screening/triage test for human appendicitis. The company is currently conducting an 800 patient FDA clinical trial in preparation for a late 2008 FDA 510(k) filing. He will also update on the exclusive license and commercialization agreement AspenBio recently signed with Novartis Animal Health, Inc. for the development and worldwide launch of AspenBio's novel bovine reproduction drugs, BoviPure LH™ and BoviPure FSH™.

About Canaccord Adams

Canaccord Adams is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients unique perspective on global investment opportunities. With operations in research, sales and trading, and investment banking, Canaccord's 225 professionals seek out emerging opportunities in the key sectors of Mining and Metals, Energy, Technology, Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth. Located in eight offices internationally, Canaccord's experienced team generates focused, actionable ideas that identify opportunity and facilitate growth.

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use in animals of economic importance. AspenBio Pharma continues to advance the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out acute appendicitis in patients complaining of abdominal pain. For more information, go to

Forward-Looking Statements

This news release includes "forward-looking statements" of AspenBio Pharma, Inc. ("APPY") as defined by the Securities and Exchange Commission (the "SEC"). All statements, other than statements of historical fact, included in the press release that address activities, events or developments that APPY believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors APPY believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of APPY. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including statements regarding the ability to successfully complete the development of, obtain FDA approval for, cost effectively manufacture and generate revenues from the appendicitis test as well as the animal products under this agreement and other new products, execute agreements required to successfully advance the company's objectives, retain the scientific management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, fluctuations in sales volumes, obtain and enforce intellectual property rights, and realization of intangible assets. Furthermore, APPY does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this news release should be considered in conjunction with the warnings and cautionary statements contained in APPY's recent filings with the SEC.

Contact Information

  • For more information contact:

    AspenBio Pharma, Inc.
    Gregory Pusey
    Tel 303-722-4008

    Investor Relations
    Liolios Group, Inc.
    Scott Liolios or Ron Both
    Tel 949-574-3860